Walmsley Targeted Again as Activists Renew Plea for New GSK CEO

GlaxoSmithKline Chief Executive Officer Emma Walmsley faces renewed calls for her ouster after Bluebell Capital Partners has taken a £10 million (about $13.7 million) stake in the company. Bluebell is urging the company board of directors to initiate a search for a new CEO ahead of the company’s 2022 split into a pharmaceutical-focused business and a consumer health business.